Takeda Phase 3 Trial Shows OS and PFS Benefits in Gastric Cancer
Takeda said Phase 3 G-HOPE-001 met both primary endpoints, with arcotatug tavatecan (TAK-921) showing statistically significant overall and progression-free survival benefits versus physician’s choice in previously treated CLDN18.2-positive advanced gastric or gastroesophageal junction cancer.
Takeda said Phase 3 G-HOPE-001 met dual primary endpoints, with arcotatug tavatecan (TAK-921) showing statistically significant OS and PFS benefits vs treatment of physician’s choice in previously treated CLDN18.2+ advanced gastric/GEJ cancer.Material DetailsContext by AI AnalystThis is a pivotal e…